Daratumumab,Talquetamab,Teclistamab,Pomalidomide
Genmab,Janssen
['darzalex', 'talquetamab', 'tecvayli']
talquetamab combination with darzalex shows high (84%) overall response rate with mpfs of 19 months in rrmm. fewer serious infections seen compared with tecvayli treatment. #asco23 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.